An in vivo drug repurposing screen and transcriptional analyses reveals the serotonin pathway and GSK3 as major therapeutic targets for NGLY1 deficiency is a research paper published in PLoS Genetics (2022). On theSindex it has a DataRank of 0.457. It has been cited 20 times.
Scored on demand from live citation data
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.457
From this paper's citation signal
Citation Network Contribution
0
Citation network not refreshed for this result
This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.
Learn more about DataRank methodology →National Institute of General Medical Sciences
Grant: R35GM124780
National Center for Advancing Translational Sciences
Grant: UL1TR002538
National Human Genome Research Institute
Grant: T32HG008962
National Institute of General Medical Sciences
Grant: F32GM139349
National Institutes of Health
Grant: 5T32HG008962-03
Training Program in Genomic Medicine
National Institutes of Health
Grant: 5R35GM124780-03
Investigating the impact of genetic variation on ER stress response and disease
National Institutes of Health
Grant: 3UL1TR002538-01S1
Utah Center for Clinical and Translational Science
National Institutes of Health
Grant: 5F32GM139349-02
Identifying Genetic Modifiers and Potential Therapeutics for NGLY1 Deficiency
Might Family through the Bertrand T. Might Fellowship
Primary Children’s Hospital Center for Personalized Medicine
FWCI
3.05
Citation Percentile
0.9%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals